USPTO 2015–2025 USPTO PatentsView US Corporation

Stimwave Technologies Incorporated

USPTO PatentsView assignee record — 39 granted patents across 10 technology areas, active 2019–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

39
Total patents granted
10
CPC technology areas
18.5
Avg claims per patent
+29%
5-year filing velocity

The verdict

Stimwave holds 39 US patents across 10 technology areas — rank #8,292 of 50,000 tracked assignees.

#8,292
of 50,000 US assignees by volume
Top 44%
by Innovation Score (37.3/100)
18.5
avg claims per patent
+29%
filing velocity, last 5 yrs

Portfolio overview

Stimwave Technologies Incorporated has been granted 39 US utility patents between 2019 and 2023, placing Stimwave Technologies Incorporated at rank #8,292 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.5 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a US Corporation, Stimwave Technologies Incorporated is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 37.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 22 grants, compared with 17 in the 2015–2019 window — a +29% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Stimwave Technologies Incorporated's 18.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Stimwave Technologies Incorporated against peers pursuing similar technology classes.

How does Stimwave compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Stimwave holds 39 patents — placing it at rank #8,292 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Stimwave's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2023

05101520 20192020202120222023 4
USPTO utility patent grants by year · 2019–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
Stimwave Technologies Incorporated patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 17 43.6%
2020 4 10.3%
2021 8 20.5%
2022 6 15.4%
2023 4 10.3%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Growing

Where it ranks

Overall rank by patents

#8,292

Across all tracked assignees

Innovation Score

37.3 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Stimwave Technologies Incorporated hold?
Stimwave Technologies Incorporated holds 39 US granted patents filed between 2019 and 2023, spanning 10 technology areas.
What is Stimwave Technologies Incorporated's Innovation Score?
Stimwave Technologies Incorporated has an Innovation Score of 37.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Stimwave Technologies Incorporated focus on?
Stimwave Technologies Incorporated's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 37 patents. The company has filed patents in 10 CPC subclasses total.
Is Stimwave Technologies Incorporated's patent filing rate increasing or decreasing?
Stimwave Technologies Incorporated's recent filing velocity is +29% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Stimwave Technologies Incorporated's patents?
Stimwave Technologies Incorporated's patents average 18.5 claims each. This falls within the standard range, providing solid legal coverage.
How is the Stimwave Technologies Incorporated patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How to use this portfolio

Stimwave's 39 grants land it in the top 44% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Stimwave ranks #8,292 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61N — see who else leads that technology area. A61N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov